CAPTRUST Financial Advisors’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$55.3K Sell
23,317
-50,295
-68% -$130K ﹤0.01% 3239
2026
Q2
$199K Buy
73,612
+31,732
+76% +$58.7K ﹤0.01% 2890
2026
Q1
$50.2K Buy
41,880
+16,346
+64% +$19.9K ﹤0.01% 2896
2025
Q4
$25.1K Buy
25,534
+6,045
+31% +$7.26K ﹤0.01% 2708
2025
Q3
$24.6K Sell
19,489
-115
-0.6% -$124 ﹤0.01% 2596
2025
Q2
$22K Buy
19,604
+3,175
+19% +$3.69K ﹤0.01% 2468
2025
Q1
$13K Buy
+16,429
New +$20.1K ﹤0.01% 2331
2022
Q3
– Sell
-474
Closed -$12K – 2712
2022
Q2
$12K Buy
474
+465
+5,167% +$12.8K ﹤0.01% 3647
2022
Q1
$0 Sell
9
-41
-82% -$1.59K ﹤0.01% 4972
2021
Q4
$3K Buy
50
+25
+100% +$1.42K ﹤0.01% 4268
2021
Q3
$1K Sell
25
-38
-60% -$2.98K ﹤0.01% 4420
2021
Q2
$5K Sell
63
-12
-16% -$967 ﹤0.01% 3855
2021
Q1
$6K Buy
+75
New +$7.19K ﹤0.01% 3648

Other funds holding FATE

CAPTRUST Financial Advisors's FATE Position: Q3 2026 in Review

CAPTRUST Financial Advisors reduced its Fate Therapeutics (FATE) stake by 68% in Q3 2026, selling an estimated $130K and leaving 23,317 shares worth $55.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3239.

CAPTRUST Financial Advisors first reported a position in FATE in Q1 2021 and has held it in 13 quarters since. The position peaked at $199K in Q2 2026. 142 funds tracked by Wall St. Rank hold FATE as of Q3 2026.

  • CAPTRUST Financial Advisors held 23,317 shares of Fate Therapeutics worth $55.3K as of Q3 2026.
  • CAPTRUST Financial Advisors sold 50,295 Fate Therapeutics shares in Q3 2026, an estimated $130K.
  • Fate Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q3 2026, its #3239 holding.
  • CAPTRUST Financial Advisors first reported a position in Fate Therapeutics in Q1 2021 and has held it in 13 quarters since.
  • CAPTRUST Financial Advisors's Fate Therapeutics position peaked at $199K in Q2 2026.
  • 142 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.